{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:50:05Z","timestamp":1774950605418,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo Europe GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.clinthera.2025.08.007","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T11:48:39Z","timestamp":1756813719000},"page":"1010-1015","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Polypharmacy and Drug-Drug Interactions in a Large Cohort of Direct Oral Anticoagulant Users With Atrial Fibrillation"],"prefix":"10.1016","volume":"47","author":[{"given":"Veronica","family":"De Angelis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ylenia","family":"Ingrasciotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Carelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Spadotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Amadori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Pagliaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa Di","family":"Giorgio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Isgr\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saveria Serena","family":"Foti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Tari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3823-3809","authenticated-orcid":false,"given":"Igor","family":"Diemberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.08.007_bib0001","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.08.007_bib0002","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.08.007_bib0003","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.08.007_bib0004","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.08.007_bib0005","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1080\/17425255.2018.1530213","article-title":"Pharmacokinetics of new oral anticoagulants: implications for use in routine care","volume":"14","author":"Ingrasciotta","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clinthera.2025.08.007_bib0006","article-title":"Atrial fibrillation: comorbidities, lifestyle, and patient factors","volume":"37","author":"Shantsila","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.clinthera.2025.08.007_bib0007","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1126\/science.1168750","article-title":"Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding","volume":"323","author":"Aller","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2025.08.007_bib0008","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"Camm","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2025.08.007_bib0009","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/europace\/euv309","article-title":"Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation","volume":"17","author":"Heidbuchel","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.clinthera.2025.08.007_bib0010","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/bcp.12836","article-title":"Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co-medication interactions","volume":"81","author":"Kreutz","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2025.08.007_bib0011","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.clinthera.2025.08.007_bib0012","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: a clinical pharmacokinetic and pharmacodynamic review","volume":"58","author":"Byon","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2025.08.007_bib0013","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.jacc.2019.12.068","article-title":"Select drug-drug interactions with direct oral anticoagulants: JACC review topic of the week","volume":"75","author":"Wiggins","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2025.08.007_bib0014","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2025.08.007_bib0015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF03256595","article-title":"Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics","volume":"9","author":"Stangier","year":"2009","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.clinthera.2025.08.007_bib0016","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1177\/030006051204000508","article-title":"Absence of clinically relevant interactions between rivaroxaban\u2014an oral, direct factor Xa inhibitor\u2014and digoxin or atorvastatin in healthy subjects","volume":"40","author":"Kubitza","year":"2012","journal-title":"J Int Med Res"},{"key":"10.1016\/j.clinthera.2025.08.007_bib0017","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s40264-017-0529-y","article-title":"Drug-induced arrhythmia: bridging the gap between pathophysiological knowledge and clinical practice","volume":"40","author":"Poluzzi","year":"2017","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2025.08.007_bib0018","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1378\/chest.10-0808","article-title":"Balancing the risk of hemorrhage vs thromboembolism in patients with atrial fibrillation: how to navigate between Scylla and Charybdis?","volume":"138","author":"Boriani","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2025.08.007_bib0019","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/17425255.2023.2287472","article-title":"Pharmacokinetics and pharmacodynamics of direct oral anticoagulants","volume":"19","author":"Hindley","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clinthera.2025.08.007_bib0020","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/S0140-6736(14)61943-7","article-title":"Association between edoxaban dose, concentration, anti-factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial","volume":"385","author":"Ruff","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2025.08.007_bib0021","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3390\/biomedicines9050445","article-title":"Laboratory monitoring of direct oral anticoagulants (DOACs)","volume":"9","author":"Dunois","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.clinthera.2025.08.007_bib0022","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009807","article-title":"Limitations of specific coagulation tests for direct oral anticoagulants: a critical analysis","volume":"7","author":"Ebner","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.clinthera.2025.08.007_bib0023","first-page":"806","article-title":"Major bleeding events in octagenarians associated with drug interactions between dabigatran and P-gp inhibitors","volume":"16","author":"Bernier","year":"2019","journal-title":"J Geriatr Cardiol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T08:56:16Z","timestamp":1774947376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825002899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0149291825002899"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.08.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Polypharmacy and Drug-Drug Interactions in a Large Cohort of Direct Oral Anticoagulant Users With Atrial Fibrillation","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}